Stakeholder dialogue

Relations with public authorities

UCB made no significant corporate political contributions in any of the countries in which it operates. However, UCB Inc. has a federal political action committee which makes federal, state and local contributions to political candidates in the U.S., as permitted by law. While UCB is not reporting significant issues or formal policy positions in 2017, UCB has been developing formal policy positions, and is actively connected with public policy makers, regulators and other stakeholders. In addition, no complaints on data privacy or breach thereof were received.

Countries in which UCB does business have laws and regulations regarding corporations’ involvement in the political process. Some of these laws set strict limits on contributions by corporations to political parties and candidates, whereas some laws prohibit them altogether.

In 2017, two complaints were received for a deviation to industry voluntary codes regarding good promotional practices in the U.K. UCB identified appropriate corrective and preventative actions.

In 2017, UCB was not involved in any action regarding laws and regulations relative to anti-competitive behavior, anti-trust or monopoly.

Relations with industry associations

UCB is a member of several global and local trade associations, e.g., Pharmaceutical Research and Manufacturers of America (PhRMA, U.S.), Biotechnology Innovation Organization (BIO, U.S.), European Federation of Pharmaceutical Industries and Associations (EFPIA, Belgium), Japan Pharmaceutical Manufacturers Association (JPMA, Japan), R&D-based Pharmaceutical Association Committee (RDPAC, China), and International Federation of Pharmaceutical Manufacturers & Associations (IFPMA, Switzerland), among others.

Jérémie and Joël, UCB (photo)

Jérémie and Joël, UCB

Considering the strategic importance, various taskforces, projects and committees dealing with current sector issues, e.g., Health, Safety and Environment, Intellectual Property, Public Policy, Global Health and Compliance, among others, have been formed that include UCB employees. As an example, Jean-Christophe Tellier, CEO, is Vice President and member of the board of EFPIA, and Treasurer and Chair of the Innovation EFPIA Board Sponsored Committees. He is also Deputy Chair of the Innovative Medicines Initiative (IMI) Governing Board, a public-private partnership between EFPIA and the European Union, represented by the European Commission. He is also a member of the CEO Steering Committee of IFPMA, as well as a member of the Board of PhRMA and BIO, Washington (U.S.), and the Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wavre (Belgium) to address solutions in the area of innovation, biotechnology and pharmaceuticals.

UCB is a member of the Access Accelerated initiative “a global partnership working towards the UN Sustainable Development Goal target to reduce premature deaths from NCDs by 2030” (accessaccelerated.org), which is managed out of the IFPMA offices and for which we make a separate financial contribution over and above our annual IFPMA membership dues.  Access Accelerated was launched in January 2017 at the annual World Economic Forum meeting in Davos, Switzerland.

Additionally, UCB is an active member of the EFPIA working group focused on the implementation of the Falsified Medicine Directive (FMD) designed to protect patients by minimizing the chances of counterfeit medicines entering into the established medicines supply chain. UCB is also part of the Transported Asset Protection Association (TAPA), Rx-360 (an international pharmaceutical Supply Chain Consortium) and EFPIA Security Forum, which collaborate with other stakeholders, to allow for benchmarking, jointly identify and discuss solutions, and ensure product integrity and transparency across the supply chain.

UCB is also one of 19 member companies of TransCelerate Biopharma Inc. TransCelerate is a not for profit organization with a mission to collaborate across the Biopharmaceutical research and development community to identify, prioritize, design and facilitate the implementation of solutions to drive efficient, effective and high quality delivery of new medicines. Through TransCelerate, UCB and the other member companies collaborate with patient engagement organizations, health authorities, investigator sites, research community and other industry groups and initiatives globally.

And finally, UCB is also a member of Patient Focused Medicines Development (PFMD),  an initiative gathering Patient organizations, pharma companies and other healthcare stakeholders.  PFMD’s goal is to improve global health by co-designing the future of healthcare for patients and with patients. Its mission is to bring together initiatives and best practices that integrate the voice of the patient throughout the lifecycle of medicines development, thereby speeding up the creation and implementation of an effective, globally standardized framework as well as the necessary tools and support to allow the adoption of the framework by various stakeholders.